ENTERO HEALTHCARE SOLU L Latest Share Price (ENTERO)
TODAY IN ONE LINE
ENTERO slumped 5.1% on above-average volume (1.8x avg), lagging Nifty's -1.1% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹6,558.27 Cr., it trades at a P/E of 52.28. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ENTERO HEALTHCARE SOLU L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.06x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 1.6%
- ●Rising Receivables vs SalesReceivables grew 35.5% outpacing sales growth of 29.9%
Latest ENTERO HEALTHCARE SOLU L News
What changed recently?
Recent events, corporate actions, and announcements.
ENTERO HEALTHCARE SOLU L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ENTERO HEALTHCARE SOLU L, framed against the sector median so the premium or discount is obvious at a glance.
ENTERO HEALTHCARE SOLU L trades at a P/E of 52.28× and P/B of 3.88×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ENTERO HEALTHCARE SOLU L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ENTERO HEALTHCARE SOLU L — derived from the latest tape, not yesterday's close.
ENTERO HEALTHCARE SOLU L last traded at ₹1,503.9 with an intraday range of ₹1,497.3–₹1,591 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1503.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1751.57 | +247.67 | +16.47% |
| R3 | 1657.87 | +153.97 | +10.24% |
| R2 | 1624.43 | +120.53 | +8.01% |
| R1 | 1564.17 | +60.27 | +4.01% |
| PIVOT | 1530.73 | 26.83 | 1.78% |
| CURRENT | 1503.90 | — | — |
| S1 | 1470.47 | -33.43 | -2.22% |
| S2 | 1437.03 | -66.87 | -4.45% |
| S3 | 1376.77 | -127.13 | -8.45% |
| S4 | 1283.07 | -220.83 | -14.68% |
ENTERO is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1535.5–₹1591
Trading Below opening range, showing Bearishness
ENTERO HEALTHCARE SOLU L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ENTERO HEALTHCARE SOLU L — consolidated or standalone — with margins, YoY growth and key ratios inline.
ENTERO HEALTHCARE SOLU L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,558.27 Cr. and reported EPS of ₹8.77.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 6,591 | 6,591 ▲ 0.0% |
| Sales Growth YoY %Derived | 29.35% | 29.35% |
| Other Income | 19 | 19 ▲ 0.0% |
| Total Income | 6,610 | 6,610 ▲ 0.0% |
| 5,911 | 5,911 ▲ 0.0% | |
| Gross ProfitDerived | 680 | 680 ▲ 0.0% |
| Gross Margin %Derived | 10.32% | 10.32% |
| 414 | 414 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 266 | 266 ▲ 0.0% |
| OPM %Derived | 4.03% | 4.03% |
| 90 | 90 ▲ 0.0% | |
| Profit Before Tax (PBT) | 179 | 179 ▲ 0.0% |
| 33 | 33 ▲ 0.0% | |
| Effective Tax %Derived | 18.68% | 18.68% |
| Total Profit for Period | 146 | 146 ▲ 0.0% |
| Less: Non-controlling Interests | 31 | 31 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 115 | 115 ▲ 0.0% |
| Net Profit Margin %Derived | 1.75% | 1.75% |
| PAT Growth YoY %Derived | 21.33% | 21.33% |
| Earnings Per Share (EPS ₹) | 26.44 | 26.44 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 6,431 | 6,431 ▲ 0.0% |
| Material Cost % of RevenueDerived | — | — |
| Employee Cost % of RevenueDerived | 3.72% | 3.72% |
| Other Cost % of RevenueDerived | 2.56% | 2.56% |
| Interest Coverage (x)Derived | 4.09x | 4.09x |
| Period | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,922 | 3,922 ▲ 0.0% | 5,096 ▲ 29.9% | 5,096 ▲ 0.0% | 6,591 ▲ 29.3% | 6,591 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 29.92% | 29.92% | 29.35% | 29.35% | |
| Other Income | 14 | 14 ▲ 0.0% | 40 ▲ 174.1% | 40 ▲ 0.0% | 19 ▼ 51.3% | 19 ▲ 0.0% | |
| Total Income | 3,937 | 3,937 ▲ 0.0% | 5,135 ▲ 30.4% | 5,135 ▲ 0.0% | 6,610 ▲ 28.7% | 6,610 ▲ 0.0% | |
3,570 | 3,570 ▲ 0.0% | 4,609 ▲ 29.1% | 4,609 ▲ 0.0% | 5,911 ▲ 28.2% | 5,911 ▲ 0.0% | ||
| Gross ProfitDerived | 352 | 352 ▲ 0.0% | 486 ▲ 38.2% | 486 ▲ 0.0% | 680 ▲ 39.9% | 680 ▲ 0.0% | |
| Gross Margin %Derived | 8.97% | 8.97% | 9.54% | 9.54% | 10.32% | 10.32% | |
240 | 240 ▲ 0.0% | 315 ▲ 31.1% | 315 ▲ 0.0% | 414 ▲ 31.7% | 414 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 112 | 112 ▲ 0.0% | 172 ▲ 53.4% | 172 ▲ 0.0% | 266 ▲ 55.0% | 266 ▲ 0.0% | |
| OPM %Derived | 2.85% | 2.85% | 3.37% | 3.37% | 4.03% | 4.03% | |
91 | 91 ▲ 0.0% | 72 ▼ 20.3% | 72 ▲ 0.0% | 90 ▲ 23.8% | 90 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 36 | 36 ▲ 0.0% | 139 ▲ 290.2% | 139 ▲ 0.0% | 179 ▲ 29.3% | 179 ▲ 0.0% | |
-4 | -4 ▲ 0.0% | 31 ▲ 837.6% | 31 ▲ 0.0% | 33 ▲ 7.0% | 33 ▲ 0.0% | ||
| Effective Tax %Derived | -11.94% | -11.94% | 22.56% | 22.56% | 18.68% | 18.68% | |
| Total Profit for Period | 40 | 40 ▲ 0.0% | 107 ▲ 169.9% | 107 ▲ 0.0% | 146 ▲ 35.7% | 146 ▲ 0.0% | |
| Less: Non-controlling Interests | 1 | 1 ▲ 0.0% | 13 ▲ 1727.6% | 13 ▲ 0.0% | 31 ▲ 144.2% | 31 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 39 | 39 ▲ 0.0% | 95 ▲ 142.5% | 95 ▲ 0.0% | 115 ▲ 21.3% | 115 ▲ 0.0% | |
| Net Profit Margin %Derived | 1.00% | 1.00% | 1.86% | 1.86% | 1.75% | 1.75% | |
| PAT Growth YoY %Derived | — | — | 142.45% | 142.45% | 21.33% | 21.33% | |
| Earnings Per Share (EPS ₹) | 8.99 | 8.99 ▲ 0.0% | 21.79 ▲ 142.4% | 21.79 ▲ 0.0% | 26.44 ▲ 21.3% | 26.44 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | 4 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 0.0% | 0 ▲ 324.7% | 0 ▲ 0.0% | -1 ▼ 221.4% | -1 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 3,901 | 3,901 ▲ 0.0% | 4,997 ▲ 28.1% | 4,997 ▲ 0.0% | 6,431 ▲ 28.7% | 6,431 ▲ 0.0% | |
| Material Cost % of RevenueDerived | — | — | — | — | — | — | |
| Employee Cost % of RevenueDerived | 3.85% | 3.85% | 3.91% | 3.91% | 3.72% | 3.72% | |
| Other Cost % of RevenueDerived | 2.27% | 2.27% | 2.27% | 2.27% | 2.56% | 2.56% | |
| Interest Coverage (x)Derived | 1.32x | 1.32x | 3.38x | 3.38x | 4.09x | 4.09x |
ENTERO HEALTHCARE SOLU L segment analysis : revenue and profit mix.
Disclosed business segments at ENTERO HEALTHCARE SOLU L with their share of revenue and profit, switchable between consolidated and standalone reporting.
ENTERO HEALTHCARE SOLU L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ENTERO HEALTHCARE SOLU L.
Our AI distills the core fundamental drivers supporting ENTERO HEALTHCARE SOLU L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ENTERO HEALTHCARE SOLU L's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM revenue surged 42.6% YoY, demonstrating robust market demand and strong growth trajectory.
Latest quarterly EPS grew 9.0% YoY with sales up 42.60% YoY, showing operational leverage.
Low debt-to-equity ratio of 0.0006x provides substantial financial flexibility for investments.
Cash flow per share ₹22.10 annually indicates solid liquidity and operational cash generation.
Current ratio 2.27 ensures strong short-term liquidity and working capital buffer.
Key Risks.
Operating margin 3.38% TTM remains thin, limiting profitability and reinvestment capacity.
Net profit margin 1.75% TTM is compressed, indicating cost pressures in distribution model.
Operating cash flow negative ₹59.72 Cr in FY2026, signaling working capital strain and cash burn.
ROE 1.60% and ROCE 1.79% significantly lag peer benchmarks, suggesting suboptimal capital efficiency.
Zero dividend yield provides no income component, limiting appeal to yield-seeking investors.
Flip Conditions.
Valuation risk. a P/E above 68 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
ENTERO HEALTHCARE SOLU L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ENTERO HEALTHCARE SOLU L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ENTERO HEALTHCARE SOLU L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ENTERO HEALTHCARE SOLU L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ENTERO HEALTHCARE SOLU L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ENTERO HEALTHCARE SOLU L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ENTERO HEALTHCARE SOLU L stood at 57.5% of traded volume, against a 20-day average of 54.3%.
ENTERO HEALTHCARE SOLU L announcements: results, concalls, ratings, M&A.
Filings ENTERO HEALTHCARE SOLU L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ENTERO HEALTHCARE SOLU L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 151 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Entero Healthcare Solutions Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
ESOP/ESOS/ESPS
Entero Healthcare Solutions Limited has informed the Exchange regarding allotment of Equity Shares upon exercise of stock options under the Entero…
Trading Window
Entero Healthcare Solutions Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Analysts/Institutional Investor Meet/Con. Call Updates
Entero Healthcare Solutions Limited has informed the Exchange about Schedule of meet
General Updates
Entero Healthcare Solutions Limited has informed the Exchange about General Updates
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
ENTERO HEALTHCARE SOLU L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ENTERO HEALTHCARE SOLU L has declared, sequenced by announce and record date.
ENTERO HEALTHCARE SOLU L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ENTERO HEALTHCARE SOLU L: business, sector, key facts.
What ENTERO HEALTHCARE SOLU L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ENTERO HEALTHCARE SOLU L operates in the Pharmacy Retail industry under the Consumer Services sector, listed as NSE: ENTERO, BSE: 544122.
Entero Healthcare Solutions Limited is a Mumbai-based Indian company established in 2018 that operates within the healthcare sector. Its core business revolves around the distribution and trading of a wide range of pharmaceutical and surgical products. This extensive portfolio caters to a diverse clientele, including retail pharmacies, hospitals, manufacturers of healthcare products, and healthcare clinics across India.
The company's distribution network encompasses several key product categories. A significant portion of its business involves medical devices, a market segment experiencing considerable growth in India. This includes a variety of products designed for both professional and home healthcare settings. Entero also distributes over-the-counter (OTC) medical products, offering readily accessible healthcare solutions to consumers.
Further diversifying its offerings, Entero distributes nutraceuticals, which are products intended to supplement dietary intake and improve overall health and well-being. This area taps into the rising consumer awareness and demand for health-conscious choices. The company also plays a role in the distribution of vaccines, contributing to crucial public health initiatives and disease prevention programs within the country.
In addition to its broader distribution activities, Entero offers specific medical devices directly to consumers. Examples of these products include nebulizers for respiratory treatments, digital thermometers for accurate temperature readings, blood pressure monitors for cardiovascular health monitoring, and adult diapers for incontinence care. This direct-to-consumer approach complements its wholesale distribution operations and solidifies its position in the healthcare market.
In summary, Entero Healthcare Solutions Limited's business model combines wholesale distribution to healthcare institutions and direct-to-consumer sales of select medical devices. Its diverse product portfolio, spanning pharmaceuticals, surgical supplies, medical devices, nutraceuticals, and vaccines, positions it as a significant player in the dynamic Indian healthcare market. The company’s relatively recent founding suggests a growth trajectory focused on expanding its market reach and product offerings within the Indian healthcare landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- ADITYA BIRLA LIFES BRAN L (ABLBL) Share PricePeer
- ACEVECTOR (ACEVECTOR) Share PricePeer
- ADVENT HOTELS INTERNATI L (ADVENTHTL) Share PricePeer
- AHLWEST (AHLWEST) Share PricePeer
- APOLLO SINDOORI HOTEL (APOLSINHOT) Share PricePeer
- Top Losers TodayScreener
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about ENTERO HEALTHCARE SOLU L (ENTERO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ENTERO HEALTHCARE SOLU L (ENTERO)?
The current share price of ENTERO HEALTHCARE SOLU L (ENTERO) is ₹1,503.90. Today, the stock has declined by ₹81.10 (5.12%), trading in a range of ₹1,497.30 to ₹1,591.00. The stock opened at ₹1,591.00 with a trading volume of 1,65,045 shares.
02Is ENTERO HEALTHCARE SOLU L stock a good investment for long-term?
ENTERO HEALTHCARE SOLU L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,558.27 Cr., P/E ratio of 52.28, ROE of 1.6%, and ROCE of 2.01%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ENTERO HEALTHCARE SOLU L stock?
The 52-week high price of ENTERO HEALTHCARE SOLU L (ENTERO) is ₹1,920.00, while the 52-week low is ₹944.00. Currently trading at ₹1,503.90, the stock is 59.31% above its 52-week low and 21.67% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ENTERO HEALTHCARE SOLU L stock at the current price?
Whether to buy ENTERO HEALTHCARE SOLU L stock at ₹1,503.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 52.28 and P/B ratio of 3.88. Today's performance shows a loss of 5.12%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ENTERO HEALTHCARE SOLU L and when is the next dividend?
ENTERO HEALTHCARE SOLU L offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹1,503.90, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ENTERO HEALTHCARE SOLU L?
ENTERO HEALTHCARE SOLU L's key financial metrics include: P/E Ratio: 52.28, P/B Ratio: 3.88, ROE: 1.6%, ROCE: 2.01%, Dividend Yield: 0%, EPS: ₹8.77, Book Value: ₹402.67, and Debt-to-Equity: 0.06. The company's market cap stands at ₹6,558.27 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ENTERO HEALTHCARE SOLU L stock performing today in the market?
ENTERO HEALTHCARE SOLU L stock opened at ₹1,591.00 and is currently trading at ₹1,503.90, showing a decline of ₹81.10 (5.12%). The intraday high is ₹1,591.00 and low is ₹1,497.30. The trading volume stands at 1,65,045 shares, indicating moderate market participation today.
08What is the P/E ratio of ENTERO HEALTHCARE SOLU L and what does it indicate?
ENTERO HEALTHCARE SOLU L has a Price-to-Earnings (P/E) ratio of 52.28, which means investors are willing to pay 52.28 for every ₹1 of earnings. With an EPS of ₹8.77, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ENTERO HEALTHCARE SOLU L (ENTERO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.